Bioanalytical Systems to Release First Quarter Fiscal 2018 Results on Tuesday, February 13, 2018

Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced today that it will report financial results for the first quarter of fiscal 2018 ended December 31, 2017, prior to the market opening on Tuesday, February 13, 2018.

If there are any questions after the press release is issued, please direct your comments to the investor relations contact noted in this release.

About Bioanalytical Systems, Inc. 

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit for more about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

Company Contact:
Jill Blumhoff
Chief Financial Officer &
Vice President of Finance
Phone: 765.497.8381

Source: Bioanalytical Systems, Inc.


Categories: Regional Business News, Healthcare and Medical News, Research, Laboratory Services, Publicly Traded, Pharmaceuticals and Biotech, Financial News

Tags: BASi, contract research, drug development, finance, financial news, medical research, pharmaceutical, pharmaceutical industry, press release, publicly traded

About Bioanalytical Systems, Inc.

View Website or Media Room

BASi provides drug developers with superior scientific research and innovative analytical instrumentation, which saves time, saves money, and saves lives, to bring revolutionary new drugs to market quickly and safely.

Jill Blumhoff
Chief Financial Officer & Vice President of Finance
Bioanalytical Systems, Inc.
2701 Kent Avenue
West Lafayette, IN 47906
United States